Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Honeywell International reports Q3 results on October 22 with analysts cutting price targets, the stock down 2.6% on the week to $207.29, and an index rebalance question sitting quietly in the background.
The analyst mood heading into next week's print is cautious without being bearish. RBC Capital lowered its target to $270 from $293 on Wednesday, one day after Citigroup cut to $270 from $279 while holding its Buy rating, and JP Morgan moved to $240 from $255 last week. All three maintained positive ratings, which means the Street is trimming its ambition rather than walking away. The mean target across the coverage universe is $255, implying roughly 23% upside from the current price. Wells Fargo initiated at Equal-Weight with a $231 target in late September, a below-consensus entry point that reflects the split between those who believe the standalone story drives a re-rating and those who think the market is paying fair value at 21.8x trailing earnings. Morgan Stanley, also at Equal-Weight, lifted its target modestly to $250 in late August. The valuation reads as neither stretched nor cheap: EV/EBITDA has drifted down about 0.3 turns over the past 30 days to 18.2x, which is consistent with the target trimming but not with an outright de-rating.
The bull case rests on execution. All three segments beat operationally in Q2, organic orders grew 16%, and management raised full-year organic growth, margin, and EPS guidance, even absorbing a $0.13 divestiture headwind. The Forge platform now connects 324,000 sites and 6.4 million assets, and services and software are expected to expand toward 45% of sales, which lifts the quality of the recurring revenue stream. The bear case is simpler: Q2 adjusted cash EPS of $2.26 missed the $2.35 to $2.45 guidance range, end markets including commercial aerospace, oil and gas, and general industrial activity remain cyclical, and at 19.3x 2027 EPS there is limited room for any execution miss. HON's EPS surprise factor score ranks in the 98th percentile, meaning it has beaten estimates far more consistently than most names, but the single-quarter miss is the number bears keep pointing to.
Positioning does not add much pressure either way. Short interest is just 1.2% of the free float, down 1.1% on the week, and the lending market is extremely loose: availability against outstanding short positions is running at 2,227%, meaning there are more than 22 shares available to borrow for every one currently shorted. Borrowing costs are 0.50%, elevated 17% on the week but still negligible in absolute terms. Options traders are leaning bullish rather than defensive: the put/call ratio is 0.30, below the 20-day mean of 0.33 and near the lower end of the past year's range of 0.24 to 0.91. The ORTEX short score of 33.8 is in the low-to-mid range and has been flat over the past two weeks, confirming there is no meaningful build of bearish conviction from short sellers into the print.
One mechanical catalyst sits on the calendar beyond earnings. ORTEX puts the probability of Honeywell being removed from the CRSP US Mega index at the December 2026 Quarterly Review at 70%. The stock needs to close above $235.21 to remain inside the index band. At $207.29, it is currently 13.5% below that line. The implied forced selling from index trackers would be $26 million, a small fraction of normal daily volume, but the accompanying share increase in the CRSP US Mid index carries an estimated $602 million of buying, also at 70% probability. Both entries have the same December 4 rank date, December 7 announcement, and December 22 trade date. These are ORTEX forecasts, not confirmed index decisions, but the asymmetry is worth noting: the deletion flow is minimal while the mid-cap inflow is large.
Retail attention has picked up ahead of the print. The ORTEX Wikipedia views signal shows interest running roughly one standard deviation above the 90-day average, not extreme, but the highest it has been in recent weeks. The next eight days, through the October 22 release, will test whether the Street's cautious optimism on the standalone story holds against whatever guidance the company provides for the second half and into 2027.
See the live data behind this article on ORTEX.
Open HON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
